Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 12/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2699291 | 0.88 | GRAMD1A (0.53) | GRAMD1AADORA1GCK | |
| SCHEMBL2700056 | 0.87 | RXFP1 (0.46) | GRAMD1AGRM5NPC1RAB9AADORA1 | |
| SCHEMBL2699242 | 0.85 | GRM5 (0.53) | GRAMD1AGRM5NPC1RAB9ADPP4 | |
| SCHEMBL20368922 | 0.84 | GRM5 (0.42) | GRAMD1AGRM5NPC1RAB9ADPP4 | |
| SCHEMBL15889120 | 0.82 | DPP4 (0.44) | GRAMD1AGRM5NPC1RAB9AGCK | |
| SCHEMBL12340949 | 0.81 | GRM5 (0.39) | GRAMD1AGRM5NPC1RAB9AGCK | |
| SCHEMBL16285307 | 0.81 | NPC1 (0.47) | GRAMD1AGRM5NPC1RAB9ADPP4 | |
| SCHEMBL16285303 | 0.81 | NPC1 (0.59) | GRAMD1AGRM5NPC1RAB9ADPP4 | |
| SCHEMBL17933982 | 0.81 | RAD52 (0.51) | GRAMD1AGRM5NPC1RAB9AADORA1 | |
| SCHEMBL2697700 | 0.78 | GRM5 (0.45) | GRM5NPC1RAB9ADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
| US-9949971-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-24 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2017-05-18 | — | — | US | disclosed |
| US-8673933-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8202881-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | GRAMD1A 2422/4885GRM5 3969/4885NPC1 4593/4885 |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | BTK, JAK2, JAK1 | GRAMD1A 2667/4885GRM5 3710/4885NPC1 4478/4885 |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | JAK2, JAK1, JAK3 | GRAMD1A 1861/4885GRM5 3667/4885NPC1 3223/4885 |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | BTK, JAK1, PDCD1 | GRAMD1A 2222/4885GRM5 4118/4885NPC1 4804/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | GRAMD1A 2422/4885GRM5 3969/4885NPC1 4593/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | GRAMD1A 2274/4885GRM5 3331/4885NPC1 4810/4885 |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | BTK, JAK2, JAK1 | GRAMD1A 2896/4885GRM5 3865/4885NPC1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.